As one of the leading causes of death globally, cancer has attracted significant interests especially from scientists. The primary objective of these scientists is to find the cancer elusive treatment. One such scientist, who has made significant contributions towards tackling cancer, is Mikhail Blagosklonny: a specialist in cancer biology and treatment therapies. With his strong academic and research background, Mikhail Blagosklonny has made significant contributions in the fight against cancer, some of which have the potential of revolutionizing cancer treatment and aging.
In addition, he has co-authored several book chapters and research reviews on cellular and molecular biology of cancer cells including their cycle, apoptosis and autophagy on tandfonline.com. His widely cited works also focus on molecular theory of aging. Towards this end, he proposed that target of rapamycin (TOR) signaling plays a significant role in prolonging cell life by inhibiting apoptosis, delaying autophagy and promoting cellular protein synthesis. These processes are vital in slowing down the aging process and hence delaying the onset of age-related diseases. Blagosklonny also proposed that since over-expression of TOR signaling inhibited autophagy leading to cancerous tumors, its regulation can help in cancer treatment. He believes understating these processes is vital in developing effective anti-cancer and anti-aging drugs.
Career and Education History
Mikhail Blagosklonny is also a scholar whose work extends beyond research. His experience played a key role in his appointment as he had worked at Ordway Research Institute as research scientist. In 2002, his academic credentials on impactjournals.com as a specialist in internal and experimental medicine with both Doctor of Medicine and Philosophy (MD and PhD) degrees saw him being appointed as New York Medical College’s associate professor. His is an alumnus of the prestigious First Pavlov State Medical University of St. Petersburg where he received both of his degrees. Blagosklonny is the current editorial leader for three peer-reviewed scientific and medical journals published weekly, biweekly and monthly: Oncotarget, Cell Cycle and Aging, respectively.